JP MORGAN/CALL/BRISTOL-MYERS SQUIBB/55/0.1/20.06.25 | Market Closed - Börse Stuttgart 04:14:26 2024-07-01 EDT | ||
| 0.092 EUR | +1.10% |
|
| Current month | +1.10% | ||
| 1 month | -2.13% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-01 | 0.092 | +1.10% |
| 24-06-28 | 0.091 | -17.27% |
| 24-06-27 | 0.11 | +10.00% |
| 24-06-25 | 0.1 | -9.09% |
| 24-06-24 | 0.11 | +25.00% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 04:14 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | J.P. Morgan |
| WKN | JK50FN |
| ISIN | DE000JK50FN2 |
| Date issued | 2024-03-15 |
| Strike | 55 $ |
| Maturity | 2025-06-20 (354 Days) |
| Parity | 10 : 1 |
| Emission price | 0.47 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.5 € |
|---|---|
| Lowest since issue | 0.083 € |
| Spread | 0.01 € |
| Spread % | 10.75% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.3
USD
Average target price
53.19
USD
Spread / Average Target
+28.80%
- Stock Market
- Warrants
- Warrant
